FASN and gastric cancer: To evaluate the effects of anti-HER2 treatments on FASN expression in HER2+ GC models, we tested its expression in HER2+ GC cell lines and in GTR0455 xenotransplants at baseline and upon incubation with L to block HER2 activity and in human specimens treated or not with T (Fig. 3).